pescador775
Contributor
- Messages
- 2,652
- Reaction score
- 11
Not long ago, physicians believed that the human CNS could not repair itself. However, recently, it has come to light that this may be wrong as there has been evidence of the brain repairing itself as opposed to "rearranging the furniture", er, circuits.
Some divers with type II DCS have made recoveries only to experience relapses. It has been claimed that this phenomenon was due to " nerve exhaustion", eg, the brain of the apparently recovered diver had only rearranged the spinal circuit paths using surviving nerves to provide extra duty, taking over from dead nerves as it were. Thus, the recovering diver was advised to "take it easy" to avoid nerve exhaustion. This is actually a retread of a hypothesis from the polio days as a way of explaining relapses.
I have some other ideas about this. I believe that some divers who have shown significant recovery only to end up crippled have undergone a new disease process brought about by a chronic, wayward immune response to injury.
I haven't been paying much attention so maybe all this is old hat. However, here is something which may be tangentially related and eventually prove to be as effective as oxygen and steroids. Long shot but worth noting:
(QUOTE)
October 11, 2007 (Washington, DC) A human monoclonal antibody administered in a single, low dose has been shown to induce remyelination in an animal model of chronic, progressive, multiple sclerosis (MS).
Presented here at the 132nd Annual Meeting of the American Neurological Association, the study, from the Mayo Clinic in Rochester, Minnesota, showed rHIgM22, a recombinant human monoclonal IgM, promoted remyelination and induced recovery of function in about 50% of quadriplegic and paraplegic mice.
"The results in these animals, who were severely impaired, were very, very, impressive. Approximately half of them experienced extensive remyelination and almost complete recovery of function. This is not just stopping the disease, this is regenerating the entire nervous system," study investigator Moses Rodriguez, MD, told Medscape Neurology & Neurosurgery.
Based on these encouraging findings, the investigators announced that they are on the verge of launching a phase 1 clinical trial of 30 MS patients to test the safety and efficacy of this agent.
Clinical Trial Planned
Some divers with type II DCS have made recoveries only to experience relapses. It has been claimed that this phenomenon was due to " nerve exhaustion", eg, the brain of the apparently recovered diver had only rearranged the spinal circuit paths using surviving nerves to provide extra duty, taking over from dead nerves as it were. Thus, the recovering diver was advised to "take it easy" to avoid nerve exhaustion. This is actually a retread of a hypothesis from the polio days as a way of explaining relapses.
I have some other ideas about this. I believe that some divers who have shown significant recovery only to end up crippled have undergone a new disease process brought about by a chronic, wayward immune response to injury.
I haven't been paying much attention so maybe all this is old hat. However, here is something which may be tangentially related and eventually prove to be as effective as oxygen and steroids. Long shot but worth noting:
(QUOTE)
October 11, 2007 (Washington, DC) A human monoclonal antibody administered in a single, low dose has been shown to induce remyelination in an animal model of chronic, progressive, multiple sclerosis (MS).
Presented here at the 132nd Annual Meeting of the American Neurological Association, the study, from the Mayo Clinic in Rochester, Minnesota, showed rHIgM22, a recombinant human monoclonal IgM, promoted remyelination and induced recovery of function in about 50% of quadriplegic and paraplegic mice.
"The results in these animals, who were severely impaired, were very, very, impressive. Approximately half of them experienced extensive remyelination and almost complete recovery of function. This is not just stopping the disease, this is regenerating the entire nervous system," study investigator Moses Rodriguez, MD, told Medscape Neurology & Neurosurgery.
Based on these encouraging findings, the investigators announced that they are on the verge of launching a phase 1 clinical trial of 30 MS patients to test the safety and efficacy of this agent.
Clinical Trial Planned
